Élan
Élan was an Irish pharmaceutical company specializing in neurology, immunology, and therapies for autoimmune and neurodegenerative diseases.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Élan Corporation plc was an Irish pharmaceutical company founded in 1969 by American businessman Don Panoz. Based in Dublin and operating with substantial commercial and research interests in the United States, the company became one of Ireland’s most prominent international drug businesses. Its activities centered on prescription medicines and biopharmaceutical research, particularly in neurology, immunology, autoimmune disease, and inflammatory disorders. Élan’s development model combined internal research with partnerships and commercialization arrangements involving larger pharmaceutical companies. Its research portfolio addressed diseases with significant unmet medical needs, including multiple sclerosis, Crohn’s disease, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, inflammatory bowel disease, and pain conditions. The company’s best-known commercial asset was natalizumab, marketed as Tysabri. The monoclonal antibody was developed and commercialized with Biogen Idec and works by limiting the movement of immune cells across blood-vessel walls into affected tissues. Tysabri became an important treatment for multiple sclerosis and Crohn’s disease and was central to Élan’s strategic value during its later years. During the late 1990s, investor confidence and market valuation placed Élan among Ireland’s most valuable publicly traded companies. Its market value on the Irish Stock Exchange reportedly exceeded €20 billion. The company subsequently suffered a severe reversal. In 2002, an accounting scandal, together with the wider deterioration in global equity markets, led to a collapse in investor confidence and a share-price decline of more than 90 percent. The episode materially changed the company’s financial position and reputation. Élan continued to invest in innovative medicines after the 2002 crisis. Its neuroscience programs included research into beta-secretase and gamma-secretase inhibitors, enzymes associated with the formation of amyloid plaques in Alzheimer’s disease. It also worked with Wyeth on bapineuzumab, an experimental antibody intended to remove toxic beta-amyloid from the brains of people with mild to moderate Alzheimer’s disease. Early clinical findings were inconclusive, and the program did not become a commercial product. These efforts illustrate Élan’s emphasis on complex biologic and disease-modifying therapies rather than a broad consumer-health portfolio. The company also faced regulatory and legal pressure. In July 2010, Élan was fined $203 million in connection with the marketing of epilepsy drugs. In February 2013, it agreed to sell its rights to market Tysabri to Biogen Idec for $3.25 billion. Later in 2013, Élan merged with Perrigo, creating Perrigo Company plc and ending Élan’s existence as a separately listed pharmaceutical company. As a result, Élan is best understood historically: an Irish-origin international drug company whose legacy rests on its neurological and immunological research, the Tysabri franchise, its dramatic 2002 financial crisis, and its eventual absorption into Perrigo.
History
Élan Corporation plc was established in Ireland in 1969 by American businessman Don Panoz. From its Dublin base, the company developed into an international pharmaceutical business with particularly strong interests in the United States. Its corporate identity was associated with specialist prescription medicines, biotechnology research, and collaborations intended to advance treatments for serious neurological and immune-mediated diseases. The company’s scientific and commercial activities expanded substantially during the late twentieth century. Élan concentrated on fields in which biologic mechanisms and targeted therapies could offer disease modification rather than only symptomatic relief. Its research interests included multiple sclerosis, Crohn’s disease, rheumatoid arthritis, inflammatory bowel disease, neurodegenerative disorders, and pain. The company also pursued Alzheimer’s disease research through programs involving beta-secretase and gamma-secretase inhibitors, enzymes believed to influence the accumulation of amyloid plaques. In partnership with Wyeth, Élan advanced bapineuzumab, a humanized monoclonal antibody designed to target beta-amyloid in Alzheimer’s disease. The program reached Phase III testing, although earlier clinical results were inconclusive and the treatment did not become an established commercial product. Élan’s most important product-related achievement was natalizumab, marketed as Tysabri. Developed and commercialized with Biogen Idec, Tysabri is a monoclonal antibody that restricts the movement of immune cells across blood-vessel walls. This mechanism made it relevant to multiple sclerosis and Crohn’s disease. Tysabri became the central asset in Élan’s later strategic planning and demonstrated the commercial potential of its specialist biotechnology portfolio. The company reached a high point in the late 1990s, when its value on the Irish Stock Exchange exceeded €20 billion. This period of rapid market appreciation was followed by a profound collapse in 2002. An accounting scandal, compounded by investor concern and a global market downturn, resulted in a share-price fall of more than 90 percent. The crisis damaged Élan’s financial standing and public reputation and became the defining setback in its corporate history. Élan continued operating as a research-oriented drug company during the following decade. It retained interests in neurological and immunological medicines while seeking to manage its portfolio through commercial partnerships and asset transactions. Regulatory and legal difficulties remained part of its history: in July 2010, the company was fined $203 million relating to the marketing of epilepsy drugs. In February 2013, Élan agreed to dispose of its rights to sell Tysabri to Biogen Idec for $3.25 billion. Later that year, Élan merged with Perrigo, forming Perrigo Company plc. The transaction ended Élan’s independent corporate existence and removed it from its former public-market listings. Its historical legacy is therefore tied to the creation of an internationally oriented Irish pharmaceutical company, the development and commercialization of important neurological and autoimmune therapies, the 2002 accounting crisis, and the eventual transfer of its principal commercial rights and corporate identity to other companies.
- 2013
Tysabri rights transferred to Biogen Idec
[1]Élan agreed to sell its rights to market Tysabri to Biogen Idec for $3.25 billion.
- 2013
Merger with Perrigo
[1]Élan merged with Perrigo, creating Perrigo Company plc and ending its independent corporate identity.
- 2010
Regulatory fine related to epilepsy-drug marketing
[1]Élan was fined $203 million in July in connection with marketing practices for epilepsy drugs.
- 2002
Accounting scandal triggers collapse in valuation
[1]An accounting scandal and broader market weakness led to a share-price decline of more than 90 percent.
- 1990
International pharmaceutical expansion
[1]Élan developed substantial commercial and business interests in the United States while remaining based in Dublin.
- 1990
Market valuation reaches historic peak
[1]During the late 1990s, Élan’s value on the Irish Stock Exchange rose above €20 billion.
- 1969
Élan is founded in Ireland
[1]American businessman Don Panoz founded the pharmaceutical company in Ireland.
Products and positioning
A research-driven biopharmaceutical company focused on complex therapies for neurological, autoimmune, and inflammatory diseases, with a strong emphasis on partnerships and specialist prescription medicines.
Neurology and autoimmune disease biologic
Tysabri
Tysabri is the brand name for natalizumab, a monoclonal antibody developed and commercialized by Élan with Biogen Idec. It limits the movement of immune cells across blood-vessel walls into tissues, including the central nervous system. The therapy became associated with treatment of multiple sclerosis and Crohn’s disease and was Élan’s most strategically important commercial product. In 2013, Élan transferred its rights to sell Tysabri to Biogen Idec.
Investigational Alzheimer’s disease biologic
Bapineuzumab
Bapineuzumab was an experimental humanized monoclonal antibody developed by Élan in collaboration with Wyeth for possible treatment of mild to moderate Alzheimer’s disease. The program was designed to target beta-amyloid and help clear the neurotoxic peptide associated with amyloid plaque accumulation. It progressed to a Phase III clinical trial, but earlier clinical findings were inconclusive and the program did not become an established marketed medicine.
Investigational Alzheimer’s disease small molecule
Semagacestat
Semagacestat was an example of Élan’s research into gamma-secretase inhibition for Alzheimer’s disease. The company studied secretase enzymes because of their suspected role in the production and accumulation of beta-amyloid plaques. The program belonged to Élan’s development pipeline rather than its marketed-product portfolio.
Biopharmaceutical research
Neurology research portfolio
Élan maintained research programs in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. These efforts included small-molecule approaches targeting secretase enzymes and biologic approaches aimed at disease-associated proteins. The portfolio reflected the company’s focus on mechanisms of neurological disease and therapies intended to alter disease progression.
Controversies
2010
Fine concerning epilepsy-drug marketing
In July 2010, Élan was fined $203 million in connection with its marketing of epilepsy drugs.
2002
Accounting scandal and market collapse
Élan experienced an accounting scandal in 2002. Investor reaction, combined with a global market slump, produced a collapse in confidence and a share-price decline of more than 90 percent.
Brand decisions
2013
Dispose of Tysabri marketing rightsStrategyBackground
Tysabri was Élan’s most significant commercial asset and was marketed with Biogen Idec for multiple sclerosis and Crohn’s disease.
Action taken
Élan agreed to sell its rights to market Tysabri to Biogen Idec for $3.25 billion.
Aftermath
The transaction preceded Élan’s merger with Perrigo later in 2013 and transferred control of the asset’s commercial rights to Biogen Idec.
Transaction value. $3.25 billion (February 2013)
2013
Merge with PerrigoM&ABackground
After years of operating as an international pharmaceutical company and following the disposal of its Tysabri rights, Élan entered a combination with Perrigo.
Action taken
Élan merged with Perrigo to form Perrigo Company plc.
Aftermath
Élan ceased to exist as a separately listed and independent pharmaceutical company.
Recent events
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/élan · Editorial policy · How profiles are compiled